针对阿尔茨海默氏病的多目标定向配体 (MTDLs) 骨多样性的分析
Uzma Azam1, Muhammad Moazzam Naseer2, Christophe Rochais3
1Department of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
European journal of medicinal chemistry
|January 23, 2025
概括
多目标定向连接体 (MTDLs) 通过同时解决多种病理途径,为阿尔茨海默病 (AD) 治疗提供了一种新的方法. 本综述探讨了使用药杂化设计的MTDL,以改进AD治疗策略.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一个复杂的挑战,需要创新的治疗策略,而不仅仅是单一的目标方法.
- 多目标定向连接体 (MTDLs) 正在成为阿尔茨海默病的有希望的治疗途径,旨在同时调节多个病理途径.
- 药混合化是MTDL设计的一个关键策略,它允许在单个分子中集成多种功能组.
研究的目的:
- 为了提供一个全面的概述的骨多样性在最近设计的MTDLs为AD治疗.
- 讨论在MTDL构建中使用的各种药用元素和核心支架.
- 突出这些MTDLs在针对多种AD病理方面的潜力,包括粉样β聚合,陶过,神经炎症和氧化应激.
主要方法:
- 关于阿尔茨海默病的MTDLs最近文献的综述.
- 在MTDL设计中分析药杂交策略.
- 检查MTDLs的结构多样性和目标病理.
主要成果:
- 广泛的MTDLs已经设计使用药杂交,展示显著的骨多样性.
- 这些MTDL结合了能够针对关键AD病理特征的药理特征.
- 审查的MTDL显示了同时解决粉样β聚合,高酸化,胆功能障碍,氧化应激和神经炎症的潜力.
结论:
- 通过药杂交设计的MTDLs代表了开发新型阿尔茨海默病治疗方法的多功能和有效策略.
- 这些MTDL的骨多样性允许定制设计,针对多种疾病途径.
- 进一步优化MTDL有望为阿尔茨海默病提供更全面的治疗方法.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.3K
相关概念视频
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
